Other search tools

About this data

The publication data currently available has been vetted by Vanderbilt faculty, staff, administrators and trainees. The data itself is retrieved directly from NCBI's PubMed and is automatically updated on a weekly basis to ensure accuracy and completeness.

If you have any questions or comments, please contact us.

Results: 11 to 20 of 107

Publication Record


Glypican-5 Increases Susceptibility to Nephrotic Damage in Diabetic Kidney.
Okamoto K, Honda K, Doi K, Ishizu T, Katagiri D, Wada T, Tomita K, Ohtake T, Kaneko T, Kobayashi S, Nangaku M, Tokunaga K, Noiri E
(2015) Am J Pathol 185: 1889-98
MeSH Terms: Adult, Aged, Animals, Cell Line, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Disease Susceptibility, Female, Fibroblast Growth Factor 2, Glomerular Mesangium, Glypicans, Humans, Hyperglycemia, Kidney, Kidney Failure, Chronic, Male, Mesangial Cells, Mice, Mice, Inbred C57BL, Mice, Knockout, Middle Aged, Nephrotic Syndrome, Podocytes, Proteinuria, Rats
Show Abstract · Added February 11, 2016
Type 2 diabetes mellitus is a leading health issue worldwide. Among cases of diabetes mellitus nephropathy (DN), the major complication of type 2 diabetes mellitus, the nephrotic phenotype is often intractable to clinical intervention and demonstrates the rapid decline of renal function to end-stage renal disease. We recently identified the gene for glypican-5 (GPC5), a cell-surface heparan sulfate proteoglycan, as conferring susceptibility for acquired nephrotic syndrome and additionally identified an association through a genome-wide association study between a variant in GPC5 and DN of type 2 diabetes mellitus. In vivo and in vitro data showed a progressive increase of GPC5 in type 2 DN along with severity; the excess was derived from glomerular mesangial cells. In this study, diabetic kidney showed that accumulation of fibroblast growth factor (Fgf)2 strikingly induced progressive proteinuria that was avoided in Gpc5 knockdown mice. The efficacy of Gpc5 inhibition was exerted through expression of the Fgf receptors 3 and 4 provoked in the diabetic kidney attributively. Extraglomerular Fgf2 was pathogenic in DN, and the deterrence of Gpc5 effectively inhibited the glomerular accumulation of Fgf2, the subsequent increase of mesangial extracellular matrix, and the podocytes' small GTPase activity. These findings elucidate the pivotal role of GPC5, identified as a susceptible gene in the genome-wide association study, in hyperglycemia-induced glomerulopathy.
Copyright © 2015 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
0 Communities
1 Members
0 Resources
25 MeSH Terms
The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.
Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP, Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups
(2015) Diabetes Care 38: 940-2
MeSH Terms: Adolescent, Autoantibodies, Biomarkers, Blood Glucose, C-Peptide, Diabetes Mellitus, Type 1, Disease Progression, Female, Glucose Tolerance Test, Humans, Hyperglycemia, Male, Patient Acuity, Risk Factors, Severity of Illness Index
Show Abstract · Added June 24, 2015
OBJECTIVE - We developed a scale to serve as a potential end point for 6-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.
RESEARCH DESIGN AND METHODS - The PS6M was developed from Diabetes Prevention Trial-Type 1 (DPT-1) data and tested in the TrialNet Pathway to Prevention Study (PTP). It is the difference between 6-month glucose sum values (30-120 min oral glucose tolerance test values) and values predicted for nonprogressors.
RESULTS - The PS6M predicted T1D in the PTP (P < 0.001). The area under the receiver operating chacteristic curve was greater (P < 0.001) for the PS6M than for the baseline-to-6-month difference. PS6M values were higher in those with two or more autoantibodies, 30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00 (P < 0.001 for all).
CONCLUSIONS - The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers.
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
1 Communities
1 Members
0 Resources
15 MeSH Terms
Skeletal muscle insulin resistance in zebrafish induces alterations in β-cell number and glucose tolerance in an age- and diet-dependent manner.
Maddison LA, Joest KE, Kammeyer RM, Chen W
(2015) Am J Physiol Endocrinol Metab 308: E662-9
MeSH Terms: Aging, Animals, Animals, Genetically Modified, Biological Transport, Cell Count, Disease Progression, Glucose, Glucose Intolerance, Green Fluorescent Proteins, Hyperglycemia, Insulin, Insulin Resistance, Insulin-Like Growth Factor I, Insulin-Secreting Cells, Luminescent Proteins, Muscle, Skeletal, Overnutrition, Receptor, IGF Type 1, Recombinant Fusion Proteins, Zebrafish, Zebrafish Proteins
Show Abstract · Added February 12, 2015
Insulin resistance creates an environment that promotes β-cell failure and development of diabetes. Understanding the events that lead from insulin resistance to diabetes is necessary for development of effective preventional and interventional strategies, and model systems that reflect the pathophysiology of disease progression are an important component toward this end. We have confirmed that insulin enhances glucose uptake in zebrafish skeletal muscle and have developed a zebrafish model of skeletal muscle insulin resistance using a dominant-negative IGF-IR. These zebrafish exhibit blunted insulin signaling and glucose uptake in the skeletal muscle, confirming insulin resistance. In young animals, we observed an increase in the number of β-cells and normal glucose tolerance that was indicative of compensation for insulin resistance. In older animals, the β-cell mass was reduced to that of control with the appearance of impaired glucose clearance but no elevation in fasting blood glucose. Combined with overnutrition, the insulin-resistant animals have an increased fasting blood glucose compared with the control animals, demonstrating that the β-cells in the insulin-resistant fish are in a vulnerable state. The relatively slow progression from insulin resistance to glucose intolerance in this model system has the potential in the future to test cooperating genes or metabolic conditions that may accelerate the development of diabetes and provide new therapeutic targets.
Copyright © 2015 the American Physiological Society.
0 Communities
1 Members
0 Resources
21 MeSH Terms
Comparison of the physiological relevance of systemic vs. portal insulin delivery to evaluate whole body glucose flux during an insulin clamp.
Farmer TD, Jenkins EC, O'Brien TP, McCoy GA, Havlik AE, Nass ER, Nicholson WE, Printz RL, Shiota M
(2015) Am J Physiol Endocrinol Metab 308: E206-22
MeSH Terms: Administration, Intravenous, Animals, Blood Glucose, Catheterization, Peripheral, Glucagon, Glucose Clamp Technique, Hyperglycemia, Insulin, Male, Portal Vein, Rats, Rats, Sprague-Dawley
Show Abstract · Added February 19, 2015
To understand the underlying pathology of metabolic diseases, such as diabetes, an accurate determination of whole body glucose flux needs to be made by a method that maintains key physiological features. One such feature is a positive differential in insulin concentration between the portal venous and systemic arterial circulation (P/S-IG). P/S-IG during the determination of the relative contribution of liver and extra-liver tissues/organs to whole body glucose flux during an insulin clamp with either systemic (SID) or portal (PID) insulin delivery was examined with insulin infusion rates of 1, 2, and 5 mU·kg(-1)·min(-1) under either euglycemic or hyperglycemic conditions in 6-h-fasted conscious normal rats. A P/S-IG was initially determined with endogenous insulin secretion to exist with a value of 2.07. During an insulin clamp, while inhibiting endogenous insulin secretion by somatostatin, P/S-IG remained at 2.2 with PID, whereas, P/S-IG disappeared completely with SID, which exhibited higher arterial and lower portal insulin levels compared with PID. Consequently, glucose disappearance rates and muscle glycogen synthetic rates were higher, but suppression of endogenous glucose production and liver glycogen synthetic rates were lower with SID compared with PID. When the insulin clamp was performed with SID at 2 and 5 mU·kg(-1)·min(-1) without managing endogenous insulin secretion under euglycemic but not hyperglycemic conditions, endogenous insulin secretion was completely suppressed with SID, and the P/S-IG disappeared. Thus, compared with PID, an insulin clamp with SID underestimates the contribution of liver in response to insulin to whole body glucose flux.
Copyright © 2015 the American Physiological Society.
0 Communities
2 Members
1 Resources
12 MeSH Terms
The hyperglycemic byproduct methylglyoxal impairs anticoagulant activity through covalent adduction of antithrombin III.
Jacobson R, Mignemi N, Rose K, O'Rear L, Sarilla S, Hamm HE, Barnett JV, Verhamme IM, Schoenecker J
(2014) Thromb Res 134: 1350-7
MeSH Terms: Anticoagulants, Antithrombin III, Blood Coagulation, Dose-Response Relationship, Drug, Heparin, Humans, Hyperglycemia, Protein Binding, Pyruvaldehyde
Show Abstract · Added January 20, 2015
INTRODUCTION - The blood coagulation system is a tightly regulated balance of procoagulant and anticoagulant factors, disruption of which can cause clinical complications. Diabetics are known to have a hypercoagulable phenotype, along with increased circulating levels of methylglyoxal (MGO) and decreased activity of the anticoagulant plasma protein antithrombin III (ATIII). MGO has been shown to inhibit ATIII activity in vitro, however the mechanism of inhibition is incompletely understood. As such, we designed this study to investigate the kinetics and mechanism of MGO-mediated ATIII inhibition.
METHODS - MGO-mediated ATIII inhibition was confirmed using inverse experiments detecting activity of the ATIII targets thrombin and factor Xa. Fluorogenic assays were performed in both PBS and plasma after incubation of ATIII with MGO, at molar ratios comparable to those observed in the plasma of diabetic patients. LC-coupled tandem mass spectrometry was utilized to investigate the exact mechanism of MGO-mediated ATIII inhibition.
RESULTS AND CONCLUSIONS - MGO concentration-dependently attenuated inhibition of thrombin and factor Xa by ATIII in PBS-based assays, both in the presence and absence of heparin. In addition, MGO concentration-dependently inhibited ATIII activity in a plasma-based system, to the level of plasma completely deficient in ATIII, again both in the presence and absence of heparin. Results from LC-MS/MS experiments revealed that MGO covalently adducts the active site Arg 393 of ATIII through two distinct glyoxalation mechanisms. We posit that active site adduction is the mechanism of MGO-mediated inhibition of ATIII, and thus contributes to the underlying pathophysiology of the diabetic hypercoagulable state and complications thereof.
Copyright © 2014 Elsevier Ltd. All rights reserved.
0 Communities
4 Members
0 Resources
9 MeSH Terms
Non-invasive bioluminescence imaging of β-cell function in obese-hyperglycemic [ob/ob] mice.
Patel M, Gleason A, O'Malley S, Connolly B, Suresch D, Virostko J, Phillips N, Lin SA, Chen TB, Klimas M, Hargreaves RJ, Sur C, Williams DL, Powers AC, Bednar B
(2014) PLoS One 9: e106693
MeSH Terms: Animals, Diabetes Mellitus, Type 2, Hyperglycemia, Islets of Langerhans, Luminescence, Mice, Obesity
Show Abstract · Added January 20, 2015
BACKGROUND - Type 2 diabetes results from failure of the β-cells to compensate for increased insulin demand due to abnormal levels of metabolic factors. The ob/ob(lep-/-) mouse has been extensively studied as an animal model of type 2 diabetes. Previous studies have shown a correlation between β-cell function and bioluminescent imaging in lean genetically engineered mice. The ability to noninvasively monitor β-cell function in ob/ob mice could provide new information on β-cell regulation in type 2 diabetes.
METHODS - To create the B6 Albino ob/ob MIP-luc mice (ob/ob-luc), the ob/ob mouse was crossed with the CD1 MIP-luc mouse. All mice were backcrossed over multiple generations to ensure the genetic background of the transgenic mice was over 96% similar to the background of the original ob/ob mouse. Animal weight, blood glucose levels, insulin in plasma, and in vivo bioluminescence (BLI) were monitored weekly or biweekly for up to 70 weeks of age. BL imaging was performed using IVIS Spectrum (Perkin Elmer) and calculated by integrating the bioluminescence signal between 5 and 10 min after i.v. injection of D-luciferin. Insulin immunohistochemistry determined islet beta cell count and insulin secretion assay determined islet insulin function.
RESULTS - There were significant increases in BLI and insulin levels as the ob/ob-luc mice aged while glucose levels gradually decreased. Ob/ob-luc were sacrificed at different time points to determine ex vivo BLI, islet function and total β-cell numbers using a cell counting training algorithm developed for the Vectra image analysis system (Perkin Elmer). The number of β-cells increased as the mice aged and all three ex vivo measurements correlated with BLI.
CONCLUSIONS - The ob/ob-luc mice can serve as a model of metabolic stress, similar to human type 2 diabetes using BLI as a surrogate marker for β-cell function.
0 Communities
2 Members
0 Resources
7 MeSH Terms
EGF receptor deletion in podocytes attenuates diabetic nephropathy.
Chen J, Chen JK, Harris RC
(2015) J Am Soc Nephrol 26: 1115-25
MeSH Terms: Albuminuria, Animals, Caspase 3, Diabetic Nephropathies, ErbB Receptors, Hyperglycemia, Male, Mice, Knockout, Podocytes, Proto-Oncogene Proteins c-bcl-2, Reactive Oxygen Species, Signal Transduction, Smad Proteins, Receptor-Regulated, Transforming Growth Factor beta, src-Family Kinases
Show Abstract · Added October 27, 2014
The generation of reactive oxygen species (ROS), particularly superoxide, by damaged or dysfunctional mitochondria has been postulated to be an initiating event in the development of diabetes complications. The glomerulus is a primary site of diabetic injury, and podocyte injury is a classic hallmark of diabetic glomerular lesions. In streptozotocin-induced type 1 diabetes, podocyte-specific EGF receptor (EGFR) knockout mice (EGFR(podKO)) and their wild-type (WT) littermates had similar levels of hyperglycemia and polyuria, but EGFR(podKO) mice had significantly less albuminuria and less podocyte loss compared with WT diabetic mice. Furthermore, EGFR(podKO) diabetic mice had less TGF-β1 expression, Smad2/3 phosphorylation, and glomerular fibronectin deposition. Immunoblotting of isolated glomerular lysates revealed that the upregulation of cleaved caspase 3 and downregulation of Bcl2 in WT diabetic mice were attenuated in EGFR(podKO) diabetic mice. Administration of the SOD mimetic mito-tempol or the NADPH oxidase inhibitor apocynin attenuated the upregulation of p-c-Src, p-EGFR, p-ERK1/2, p-Smad2/3, and TGF-β1 expression and prevented the alteration of cleaved caspase 3 and Bcl2 expression in glomeruli of WT diabetic mice. High-glucose treatment of cultured mouse podocytes induced similar alterations in the production of ROS; phosphorylation of c-Src, EGFR, and Smad2/3; and expression of TGF-β1, cleaved caspase 3, and Bcl2. These alterations were inhibited by treatment with mito-tempol or apocynin or by inhibiting EGFR expression or activity. Thus, results of our studies utilizing mice with podocyte-specific EGFR deletion demonstrate that EGFR activation has a major role in activating pathways that mediate podocyte injury and loss in diabetic nephropathy.
Copyright © 2015 by the American Society of Nephrology.
1 Communities
1 Members
0 Resources
15 MeSH Terms
Dietary sodium restriction decreases insulin secretion without affecting insulin sensitivity in humans.
Luther JM, Byrne LM, Yu C, Wang TJ, Brown NJ
(2014) J Clin Endocrinol Metab 99: E1895-902
MeSH Terms: Adult, Aldosterone, Blood Glucose, Cross-Over Studies, Diet, Sodium-Restricted, Double-Blind Method, Female, Glucose Clamp Technique, Healthy Volunteers, Humans, Hyperglycemia, Insulin, Insulin Resistance, Insulin Secretion, Male, Renin, Renin-Angiotensin System, Sodium, Dietary
Show Abstract · Added October 27, 2014
CONTEXT - Interruption of the renin-angiotensin-aldosterone system prevents incident diabetes in high-risk individuals, although the mechanism remains unclear.
OBJECTIVE - To test the hypothesis that activation of the endogenous renin-angiotensin-aldosterone system or exogenous aldosterone impairs insulin secretion in humans.
DESIGN - We conducted a randomized, blinded crossover study of aldosterone vs vehicle and compared the effects of a low-sodium versus a high-sodium diet.
SETTING - Academic clinical research center.
PARTICIPANTS - Healthy, nondiabetic, normotensive volunteers.
INTERVENTIONS - Infusion of exogenous aldosterone (0.7 μg/kg/h for 12.5 h) or vehicle during low or high sodium intake. Low sodium (20 mmol/d; n = 12) vs high sodium (160 mmol/d; n = 17) intake for 5-7 days.
MAIN OUTCOME MEASURES - Change in acute insulin secretory response assessed during hyperglycemic clamps while in sodium balance during a low-sodium vs high-sodium diet during aldosterone vs vehicle.
RESULTS - A low-sodium diet increased endogenous aldosterone and plasma renin activity, and acute glucose-stimulated insulin (-16.0 ± 5.6%; P = .007) and C-peptide responses (-21.8 ± 8.4%; P = .014) were decreased, whereas the insulin sensitivity index was unchanged (-1.0 ± 10.7%; P = .98). Aldosterone infusion did not affect the acute insulin response (+1.8 ± 4.8%; P = .72) or insulin sensitivity index (+2.0 ± 8.8%; P = .78). Systolic blood pressure and serum potassium were similar during low and high sodium intake and during aldosterone infusion.
CONCLUSIONS - Low dietary sodium intake reduces insulin secretion in humans, independent of insulin sensitivity.
0 Communities
2 Members
0 Resources
18 MeSH Terms
Glucotoxicity targets hepatic glucokinase in Zucker diabetic fatty rats, a model of type 2 diabetes associated with obesity.
Ueta K, O'Brien TP, McCoy GA, Kim K, Healey EC, Farmer TD, Donahue EP, Condren AB, Printz RL, Shiota M
(2014) Am J Physiol Endocrinol Metab 306: E1225-38
MeSH Terms: Animals, Body Weight, Canagliflozin, Diabetes Mellitus, Type 2, Eating, Glucagon, Glucokinase, Glucose, Glucose Clamp Technique, Glucosides, Hyperglycemia, Hyperinsulinism, Immunohistochemistry, Liver, Male, Obesity, Organ Size, Oxygen Consumption, RNA, Messenger, Rats, Rats, Zucker, Sodium-Glucose Transporter 2 Inhibitors, Thiophenes
Show Abstract · Added February 19, 2015
A loss of glucose effectiveness to suppress hepatic glucose production as well as increase hepatic glucose uptake and storage as glycogen is associated with a defective increase in glucose phosphorylation catalyzed by glucokinase (GK) in Zucker diabetic fatty (ZDF) rats. We extended these observations by investigating the role of persistent hyperglycemia (glucotoxicity) in the development of impaired hepatic GK activity in ZDF rats. We measured expression and localization of GK and GK regulatory protein (GKRP), translocation of GK, and hepatic glucose flux in response to a gastric mixed meal load (MMT) and hyperglycemic hyperinsulinemic clamp after 1 or 6 wk of treatment with the sodium-glucose transporter 2 inhibitor (canaglifrozin) that was used to correct the persistent hyperglycemia of ZDF rats. Defective augmentation of glucose phosphorylation in response to a rise in plasma glucose in ZDF rats was associated with the coresidency of GKRP with GK in the cytoplasm in the midstage of diabetes, which was followed by a decrease in GK protein levels due to impaired posttranscriptional processing in the late stage of diabetes. Correcting hyperglycemia from the middle diabetic stage normalized the rate of glucose phosphorylation by maintaining GK protein levels, restoring normal nuclear residency of GK and GKRP under basal conditions and normalizing translocation of GK from the nucleus to the cytoplasm, with GKRP remaining in the nucleus in response to a rise in plasma glucose. This improved the liver's metabolic ability to respond to hyperglycemic hyperinsulinemia. Glucotoxicity is responsible for loss of glucose effectiveness and is associated with altered GK regulation in the ZDF rat.
Copyright © 2014 the American Physiological Society.
0 Communities
1 Members
0 Resources
23 MeSH Terms
Characterization of vector-based delivery of neurogenin-3 in murine diabetes.
Phillips N, Kay MA
(2014) Hum Gene Ther 25: 651-61
MeSH Terms: Animals, Basic Helix-Loop-Helix Transcription Factors, Cellular Reprogramming, Diabetes Mellitus, Experimental, Genetic Therapy, Genetic Vectors, Hyperglycemia, Insulin-Secreting Cells, Mice, Nerve Tissue Proteins
Show Abstract · Added October 19, 2016
Treatment of type 1 diabetes with gene transfer-induced cellular reprogramming requires a pancreatic transcription factor such as Neurogenin-3 (Ngn3) and as of yet unknown component of the adenoviral particle. Despite intensive study, there are many unsolved processes related to the mechanisms and physiological parameters related to diabetes correction using this approach. While we confirm that systemic delivery of adenovirus (Ad)-Ngn3 provides long-lasting correction of streptozotocin (STZ)-induced hyperglycemia and restoration of growth curves, we found that insulin levels and glucose tolerance tests are not fully restored. By altering the innate and antigen-specific immune responses, we establish that the former likely plays some role in the reprogramming process. Interestingly, Ad-hNgn3 therapy in diabetic animals appeared to protect them from secondary STZ challenge. The resistance to secondary STZ response was more pronounced at later time points, indicating that a period of cell maturation and/or expansion may be required in order to promote lasting correction. More importantly, these results suggest that the long-term reprogrammed cells are not fully reprogrammed into β-cells, which in the case of autoimmune diabetes may be advantageous in a long-term treatment strategy. Finally, we show that the prophylactic administration of Ad-hNgn3 before diabetic induction protected mice from developing hyperglycemia, demonstrating the potential for reducing or eliminating disease progression should treatment be initiated early or before onset of symptoms.
0 Communities
1 Members
0 Resources
10 MeSH Terms